Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits
J Smith-Palmer, K Cerri, W Valentine - BMC infectious diseases, 2015 - Springer
Background The goal of chronic hepatitis C treatment is to remove the virus to avoid
progression of HCV-related disease. Sustained virologic response (SVR) is the most widely …
progression of HCV-related disease. Sustained virologic response (SVR) is the most widely …
Novel therapies for hepatitis C—one pill fits all?
MP Manns, T Von Hahn - Nature reviews Drug discovery, 2013 - nature.com
Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense
research and development efforts, a large number of direct-acting antiviral drugs are now …
research and development efforts, a large number of direct-acting antiviral drugs are now …
Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and …
C Crossan, EA Tsochatzis, L Longworth, K Gurusamy… - 2015 - bura.brunel.ac.uk
BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis
in chronic liver disease; however, it is invasive, with the potential for serious complications …
in chronic liver disease; however, it is invasive, with the potential for serious complications …
[PDF][PDF] New horizons in hepatitis C antiviral therapy with direct‐acting antivirals
A Aghemo, R De Francesco - Hepatology, 2013 - Wiley Online Library
Most direct‐acting antivirals (DAAs) that are being developed as therapy against hepatitis C
virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter …
virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter …
[PDF][PDF] Cost‐effectiveness of hepatitis C treatment for patients in early stages of liver disease
AJ Leidner, HW Chesson, F Xu, JW Ward… - …, 2015 - Wiley Online Library
New treatments for hepatitis C virus (HCV) may be highly effective but are associated with
substantial costs that may compel clinicians and patients to consider delaying treatment …
substantial costs that may compel clinicians and patients to consider delaying treatment …
[HTML][HTML] Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving
Background & Aims Direct-acting antivirals (DAAs) are effective in treatment of hepatitis C
virus (HCV) genotype 1 infection, but their cost and value have been debated. We performed …
virus (HCV) genotype 1 infection, but their cost and value have been debated. We performed …
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in US incarcerated populations: a cost-effectiveness analysis
S Liu, D Watcha, M Holodniy… - Annals of internal …, 2014 - acpjournals.org
Background: Prevalence of chronic hepatitis C virus (HCV) infection is high among
incarcerated persons in the United States. New, short-duration, high-efficacy therapies may …
incarcerated persons in the United States. New, short-duration, high-efficacy therapies may …
Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals
J Chhatwal, T He, MA Lopez-Olivo - Pharmacoeconomics, 2016 - Springer
Background New direct-acting antivirals (DAAs) are highly effective for hepatitis C virus
(HCV) treatment. However, their prices have been widely debated. Decision-analytic models …
(HCV) treatment. However, their prices have been widely debated. Decision-analytic models …
Direct-acting antiviral agents for hepatitis C virus infection
JJ Kiser, C Flexner - Annual review of pharmacology and …, 2013 - annualreviews.org
Two selective inhibitors of the hepatitis C virus (HCV) protease nearly double the cure rates
for this infection when combined with peginterferon alfa and ribavirin. These drugs …
for this infection when combined with peginterferon alfa and ribavirin. These drugs …
Is individualized medicine more cost-effective? A systematic review
MHM Hatz, K Schremser, WH Rogowski - Pharmacoeconomics, 2014 - Springer
Background Individualized medicine (IM) is a rapidly evolving field that is associated with
both visions of more effective care at lower costs and fears of highly priced, low-value …
both visions of more effective care at lower costs and fears of highly priced, low-value …